MedTrace Logo

Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair

NCT02302053 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-11-26

No results posted yet for this study

Summary

The New Viviscal Professional Strength is an oral food supplement specifically designed to promote hair growth for women suffering from temporary thinning hair. It does not contain hormones, drugs or industry by-products. Viviscal has been marketed in Europe for over 15 years.

The purpose of this clinical research study is to evaluate certain physiological effects of Viviscal compared to placebo in forty (40) female subjects, ages 21-75 years of age with self-perceived thinning hair associated with poor diet, stress, hormonal influences or abnormal menstrual cycles when compared to using the placebo tablet.

Conditions

  • Hair Thinning

Interventions

DIETARY_SUPPLEMENT

New Viviscal Professional Supplement

The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.

DIETARY_SUPPLEMENT

Placebo tablets

The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.

Sponsors & Collaborators

  • Irish Response t/a Lifes2good

    collaborator INDUSTRY

  • DeNova Research

    collaborator OTHER

  • Ablon Skin Institute Research Center

    lead OTHER

Principal Investigators

  • Glynis Ablon, MD, FAAD · Director Ablon Skin Institute Research Center

  • Steven Dayan, MD, FACS · Director DeNova Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-02-28
Completion
2014-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02302053 on ClinicalTrials.gov